11 March 2016: A novel drug proven to reduce the risk of disease progression by 79% as well as three new European Centres of Excellence, offer new hope to patients with inoperable metastatic advanced midgut neuroendocrine cancer.
Today, cancer experts at the 13th Annual Conference of the European Neuroendocrine Tumor Society (ENETS) for the diagnosis and treatment of Neuroendocrine Tumour Disease in Barcelona (9-11 March 2016), welcome this major treatment advance and call for more European accredited centres of excellence to further improve treatment outcomes for patients.
A novel drug, Lutetium-DOTATATE (Lutathera), has been found to have significantly lowered the risk for disease progression or death among patients with previously treated, advanced midgut neuroendocrine tumours, according to the phase III results of the NETTER-1 trial.1Compared with patients treated with octreotide LAR 60 mg, treatment with 177Lutetium-DOTATATE resulted in about an 80% decreased risk for progression or death.
This phase III trial tested 177Lutetium-DOTATATE, a peptide receptor radionuclide therapy (PRRT) that combines hormone therapy and radiotherapy. The study included 230 patients with inoperable, progressive disease and randomly assigned them to four administrations of 177Lutetium-DOTATATE 7.4 GBq every 8 weeks or octreotide LAR 60 mg every 4 weeks.
At data analysis, 23 patients in the 177Lutetium-DOTATATE group had confirmed disease progression or death compared with 67 patients in the octreotide group.
In addition to this exciting development, ENETS have established a rigorous quality procedure for the accreditation of Centres of Excellence in the treatment of neuroendocrine tumours. This programme is extremely successful with 34 centres now accredited and a further three, two in the UK and the first of its kind in Poland, to receive accreditation at the conference. ENETS presented the auditing process to European Parliament in Brussels and it may yet serve as a paradigm for the planned European Reference Networks.
“Exciting new data with pharma sponsored trials such as Lutetium-DOTATATE as well as other recent clinical trials such as RADIANT 4 with everolimus and TELESTAR with telotristat etiprate together with ENETS work leading the way in developing accredited new centres of excellence, offers real hope for many patients with advanced endocrine cancer whose second-line therapeutic options have been so limited,” explains Professor Martyn Caplin, International Gastrointestinal and Pancreatic Cancer specialist.
“With the results of the Netter-1 trial and the significant ongoing work to demonstrate the effectiveness of other PRRT agents, hopefully the door will now open to making this therapy available and affordable throughout the US and around the world ” said Ron Hollander, Executive Director of the Neuroendocrine Tumor Research Foundation and President of the International Neuroendocrine Cancer Alliance (INCA).”
ENDS
For all media enquiries or interviews with Professor Martyn Caplin, please contact Luke Paskins at Spink:
01444 811099 / [email protected]
About Professor Martyn Caplin
Professor Martyn Caplin, BSc Hons, DM, FRCP is Professor of Gastroenterology & GI Neuroendocrinology at the Royal Free Hospital and University College London. In addition to being the 2014-2016 Chairman of ENETS, he has been with ENETS since its foundation in 2004. He also leads The Royal Free Hospital’s “European Neuroendocrine Tumour Society’s Centre of Excellence”, as well as both scientific and clinical research programmes into neuroendocrine tumours. Professor Caplin has recently received a Lifetime Achievement Award from the UK & Ireland Neuroendocrine Tumour Society (UKI NETS) in recognition of his clinical leadership and research in the field of NETs.
Luke Paskins
01444 811099
www.spinkhealth.com
@spinkhealth
1. 177Lu-Dotatate Significantly Improves Progression-Free Survival in Patients with Midgut Neuroendocrine Tumours: Results of the Phase III NETTER-1 Trial Jonathan Strosberg1, Edward Wolin2, Beth Chasen3, Matthew Kulke4, David Bushnell5, Martyn Caplin6, Richard P. Baum7, Erik Mittra8, Timothy Hobday9, Andrew Hendifar10, Kjell Oberg11, Maribel Lopera Sierra12, Philippe Ruszniewski13, Dik Kwekkeboom14 on behalf of the NETTER-1 study group.
